Oxford University says trial illness may not be linked to AstraZeneca's COVID-19 vaccine

The adverse events that led to a halt in AstraZeneca's COVID-19 vaccine trials may not have been associated with the vaccine itself.
That's according to Oxford University, the global biopharmaceutical company's vaccine research partner, which explained that following independent review, these illnesses were considered unlikely to be associated with the vaccine.
It added in a document sent out to trial participants that there was insufficient evidence to say for certain that these symptoms were or were not related to the vaccine.
It noted that the independent reviewers recommended that the trial should continue.